HAYWARD, Calif.--(BUSINESS WIRE)--Nov. 3, 2004--IMPAX
Laboratories, Inc. (Nasdaq NM:IPXL) today announced that the Company
has postponed its release of 2004 third quarter financial results to
Tuesday, November 9, 2004 in order to allow its independent auditors
more time to complete their review of the Company's third quarter
financial statements, including the timing of certain customer credits
on bupropion products marketed by a strategic partner. Results were
originally scheduled to be announced on Thursday, November 4, 2004.
Management will host an investment conference call beginning at
9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) on November 9, 2004 to
discuss these results and to answer questions.
To participate in the live call by telephone, please dial (888)
803-7396 from the U.S., or for international callers, please dial
(706) 634-1052.
Those interested in listening to the conference call live via the
Internet may do so by visiting the Company's Web site at
www.impaxlabs.com. To listen to the live call, please go to the Web
site 15 minutes prior to its start to register, download, and install
the necessary audio software.
A replay will be available on the Company Web site for 14 days
beginning November 9, 2004. A telephone replay will be available from
1:00 p.m. Eastern Time November 9 through 11:59 p.m. Eastern Time
November 11, by dialing (800) 642-1687 from the U.S., or (706)
645-9291 for international callers, and entering conference ID number
1751374.
IMPAX Laboratories, Inc. is a technology based specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of branded products.
IMPAX markets its generic products through its Global Pharmaceuticals
division and intends to market its branded products through the IMPAX
Pharmaceuticals division. Additionally, where strategically
appropriate, IMPAX has developed marketing partnerships to fully
leverage its technology platform. IMPAX Laboratories is headquartered
in Hayward, California, and has a full range of capabilities in its
Hayward and Philadelphia facilities. For more information, please
visit the Company's Web site at: www.impaxlabs.com.
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995:
To the extent any statements made in this news release contain
information that is not historical, these statements are
forward-looking in nature and express the beliefs and expectations of
management. Such statements are based on current expectations and
involve a number of known and unknown risks and uncertainties that
could cause IMPAX's future results, performance or achievements to
differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Such risks
and uncertainties include, but are not limited to, IMPAX's ability to
obtain sufficient capital to fund its operations, the difficulty of
predicting FDA filings and approvals, consumer acceptance and demand
for new pharmaceutical products, the impact of competitive products
and pricing, IMPAX's ability to successfully develop and commercialize
pharmaceutical products, IMPAX's reliance on key strategic alliances,
the uncertainty of patent litigation, the availability of raw
materials, the regulatory environment, dependence on patent and other
protection for innovative products, exposure to product liability
claims, fluctuations in operating results and other risks detailed
from time to time in IMPAX's filings with the Securities and Exchange
Commission. Forward-looking statements speak only as to the date on
which they are made, and IMPAX undertakes no obligation to update
publicly or revise any forward-looking statement, regardless of
whether new information becomes available, future developments occur
or otherwise.
CONTACT: IMPAX Laboratories, Inc.
Barry R. Edwards, (215) 933-0323 Ext. 4360
Larry Hsu, (510) 476-2000 Ext. 1111
Cornel C. Spiegler, (215) 289-2220 Ext. 1706
www.impaxlabs.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz (kgolodetz@lhai.com)
(212) 838-3777
Bruce Voss (bvoss@lhai.com)
(310) 691-7100
www.lhai.com
SOURCE: IMPAX Laboratories, Inc.